Serono's Oral Cladribine for the Treatment of Multiple Sclerosis Awarded Fast Track Status By FDA RedNova Thu, 21 Sep 2006 1:10 AM PDT GENEVA, Switzerland, September 21 /PRNewswire-FirstCall/ -- Serono (virt-x: SEO and NYSE: SRA) announced today that oral cladribine has been designated a Fast Track product by the US Food and Drug Administration (FDA). This designation covers patients with relapsing forms of multiple sclerosis.

FDA fast-tracks Serono's oral MS drug AP via Yahoo! News Thu, 21 Sep 2006 4:32 AM PDT Swiss biotech firm Serono SA, which earlier Thursday agreed to sell a majority stake in the company to German drugmaker Merck KGaA for $13.31 billion, said its oral cladribine treatment for multiple sclerosis has received "fast-track" status from the U.S. Food and Drug Administration.

FDA Fast-Tracks Serono's Oral MS Drug CBS 13 Sacramento Thu, 21 Sep 2006 5:24 AM PDT Swiss biotech firm Serono SA, which earlier Thursday agreed to sell a majority stake in the company to German drugmaker Merck KGaA for $13.31 billion, said its oral cladribine treatment for multiple sclerosis has received "fast-track" status from the U.S. Food and Drug Administration. CBS News Interactive: Timeline Of Vioxx-Related Events

Vitamin May Help Against MS Nerve Damage RedNova Wed, 20 Sep 2006 4:09 PM PDT A Children's Hospital Boston study finds strong evidence that nicotinamide, a form of vitamin B3, may protect against nerve damage in multiple sclerosis. A team led by Dr.

Vitamin B3 May Help MS MedicineNet.com Wed, 20 Sep 2006 12:27 PM PDT Title: Vitamin B3 May Help MS Category: Health News Created: 9/20/2006 Last Editorial Review: 9/20/2006

Vitamin Shows Promise for MS Patients
MedicineNet.com Wed, 20 Sep 2006 12:28 PM PDT
Title: Vitamin Shows Promise for MS Patients Category: Health News Created: 9/20/2006 2:05:00 AM Last Editorial Review: 9/20/2006 2:04:34 AM

---

rituximab Multiple Sclerosis

Genentech and Biogen Idec announce positive results from trial of ...
Therapeutics Daily (subscription) (press release) - Newtown,PA,USA
... (BIIB) announced that a Phase II study of Rituxan (Rituximab) for relapsing-remitting multiple sclerosis (RRMS) met its primary endpoint. ...

---

tovaxin

Positive results for Opexa in ongoing MS study
Pharmaceutical Business Review - USA
Opexa Therapeutics has said that after positive data from a phase I/II trial assessing Tovaxin for the treatment of multiple sclerosis, it has initiated a ...

Opexa Commences Phase IIb Multiple Sclerosis Study; Reports ...
Genetic Engineering News (press release) - Larchmont,NY,USA
... Company's development including: -- Its Phase IIb study with Tovaxin(TM) for the treatment of multiple sclerosis has begun. More than ...

Market Report -- In Play (OPXA)
MSN Money - USA
... IIb Multiple Sclerosis Study; Reports Positive Phase I/II Data; Provides Update on Preclinical Progress Co announces its Phase IIb study with Tovaxin for the ...

Opexa launches phase 2b trial of MS drug
United Press International - USA
THE WOODLANDS, Texas, Sept. 18 (UPI) -- Opexa said Monday it has begun a US phase 2b study of Tovaxin T Cell vaccine for the treatment of multiple sclerosis. ...

---

tysabri

A Billionaire Sells His Biotech
Forbes - USA
... thanks largely to Rebif, a multiple sclerosis treatment that has done well in the wake of the safety issues that faced Biogen Idec's Tysabri, which was ...

Nutra Pharma Announces ReceptoPharm to Be a Featured Speaker at ...
PharmaLive.com (press release) - Newtown,PA,USA
... The most recently available drug, Tysabri, was voluntarily pulled from the marketplace in February 2005 by the drug's manufacturers, Biogen-Idec (Nasdaq: BIIB ...

Big Pharma's biotech strategy: Buy it
CNNMoney.com - USA
... close eye on MedImmune (Charts), maker of experimental heart disease treatment Numax, and Biogen, maker of the FDA-approved multiple sclerosis treatment Tysabri ...

Another Partner for Biogen
MSNBC - USA
... to Biogen investors, it's because PML is the ultra-rare condition, usually occurring in people with immune deficiencies, that caused Tysabri, the company's ...
See all stories on this topic